SciSparc (SPRC) Stock Price, News & Analysis

Company Overview

SciSparc N.V. (NASDAQ: SPRC) is a Belgium‐based medical technology company that develops and commercializes non‐invasive neuromodulation platforms for the treatment of central and peripheral nervous system disorders. The company’s proprietary technology applies focused ultrasound waves to modulate neural activity without surgical intervention, offering a precision approach to address conditions such as treatment‐resistant depression, chronic pain and movement disorders. SciSparc’s research and development efforts are centered on refining device parameters to optimize safety, efficacy and patient comfort.

The company’s flagship product line, branded under the SPARC platform, comprises a suite of ultrasound neuromodulation devices designed for outpatient clinic use. These devices deliver controlled ultrasound pulses to targeted brain regions or peripheral nerves, aiming to restore balanced neural signaling and alleviate clinical symptoms. SciSparc has initiated multiple early‐stage clinical trials across Europe to evaluate safety, tolerability and preliminary efficacy in patients with major depressive disorder and neuropathic pain, with promising initial data supporting further development.

Founded in 2019 and headquartered in Mont‐Saint‐Guibert, Belgium, SciSparc operates research partnerships with leading academic institutions and clinical centers across Europe. The company plans to expand its footprint in North America through regulatory filings and strategic collaborations, while maintaining manufacturing capabilities to support pilot product launches. SciSparc’s regulatory strategy includes pursuing CE marking in the European Union, with future filings planned for the U.S. Food and Drug Administration.

Led by a management team with deep expertise in medical device innovation, neuroscience and regulatory affairs, SciSparc draws on decades of combined experience from global healthcare and life sciences organizations. The executive leadership includes the company’s founder and CEO, Dr. Stéphane Bolli, supported by seasoned professionals in clinical development, product engineering and commercial operations. Together, they guide SciSparc’s mission to bring non‐invasive, ultrasound‐based neuromodulation therapies to patients in need worldwide.

Key Stats

• Today's Range: $7.20 to $8.00
• 50-Day Range: $6.19 to $7.70
• 52-Week Range: $4.14 to $37.59
• Volume: 28,346 shs
• Average Volume: 190,717 shs
• Market Capitalization: $3.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SciSparc Stock Analysis - MarketRank™

SciSparc scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for SciSparc.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

SciSparc has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.80% of the float of SciSparc has been sold short.

Short Interest Ratio / Days to Cover

SciSparc has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SciSparc has recently decreased by 97.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SciSparc does not currently pay a dividend.

Dividend Growth

SciSparc does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.80% of the float of SciSparc has been sold short.

Short Interest Ratio / Days to Cover

SciSparc has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SciSparc has recently decreased by 97.69%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.93

News Sentiment

SciSparc has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for SciSparc this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SciSparc insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.52% of the stock of SciSparc is held by insiders.

Percentage Held by Institutions

Only 25.06% of the stock of SciSparc is held by institutions.

SPRC Stock Analysis - Frequently Asked Questions

How have SPRC shares performed this year?

SciSparc's stock was trading at $7.56 at the beginning of the year. Since then, SPRC shares have decreased by 2.4% and is now trading at $7.38.

When did SciSparc's stock split?

Shares of SciSparc reverse split on Thursday, July 3rd 2025.The 1-21 reverse split was announced on Tuesday, June 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of SciSparc?

Shares of SPRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SciSparc own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SciSparc investors own include Solid Power (SLDP), Sangamo Therapeutics (SGMO), Plug Power (PLUG), Mullen Automotive (MULN), NVIDIA (NVDA), Verb Technology (VERB) and Avalon GloboCare (ALBT).

Company Calendar

• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRC
• CIK: 1611746
• Web: scisparc.com
• Phone: 972-3717-5777
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.36
• Quick Ratio: 5.28

Sales & Book Value

• Annual Sales: $1.31 million
• Price / Sales: 2.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.13 per share
• Price / Book: 0.41

Miscellaneous

• Outstanding Shares: 530,000
• Free Float: 527,000
• Market Cap: $3.91 million
• Optionable: Not Optionable
• Beta: 0.72